In a significant move to strengthen the intellectual property (IP) landscape within Karnataka’s academic institutions, the International Institute of Information Technology Bangalore (IIIT-B) organized a one-day workshop titled “Patent Proficiency for Academic Innovators.” The event, held under the New Age Innovation Network (NAIN) 2.0 program, aimed to equip students, faculty, and innovators with practical knowledge on innovation.
Empowering Academic Innovators
The workshop was conducted in collaboration with Startup Karnataka and the Department of IT, BT, Government of Karnataka. Distinguished speakers included Nithin Chakki, KAS, General Manager of the Karnataka Innovation and Technology Society (KITS); Cmd. Sridhar, Registrar of IIIT-B; Prakash Balekundri, CEO of Unique Patent Solutions. They emphasized the critical role of intellectual property rights (IPR) in translating academic research into market-ready solutions.
The sessions provided attendees with insights into identifying patentable ideas, navigating the patent filing process, and enhancing the quality of patent applications. Real-world case studies and expert guidance were integral to the workshop, offering participants a comprehensive understanding of the journey from research ideation to securing intellectual property.
Extending Reach to Tier-2 Institutions
As an anchor institute for the NAIN 2.0 program, IIIT-B extended the workshop’s benefits to several affiliated institutions, including Jain (Deemed-to-be University), Bapuji Institute of Engineering & Technology in Davangere, Malnad College of Engineering, Mangalore Institute of Technology and Engineering, and St. Philomena College in Puttur. This initiative reflects a growing commitment among Tier-2 city institutions to build robust IPR ecosystems and contribute to the state’s innovation goals.
Fostering a Culture of Innovation
Dr. Lakshmi Jagannathan stressed the importance of guiding these innovators in protecting their work, commercializing it, and contributing meaningfully to the economy. The workshop also focused on strengthening the capabilities of Technology Transfer Offices (TTOs) within institutions, emphasizing their role in bridging the gap between innovative ideas and IP protection.
About IIIT-Bangalore and Its Innovation Centre
The IIIT-B Innovation Centre serves as a dynamic hub for fostering innovation, entrepreneurship, and cutting-edge research. As a not-for-profit Section 8 company hosted by IIIT-Bangalore, the centre offers state-of-the-art incubation facilities, advanced labs, and access to expert mentorship. It supports projects across various domains, including artificial intelligence, data science, Internet of Things (IoT), and digital health. Having supported over 100 startups, the centre plays a pivotal role in nurturing emerging talent and driving technological advancements, positioning itself as a key enabler of innovation and collaboration in India’s tech ecosystem.
IIIT-Bangalore, Situated in the heart of Electronic City, Bangalore, it holds a prominent position in the academic landscape and is graded A+ by the National Assessment and Accreditation Council (NAAC).
The successful execution of the “Patent Proficiency for Academic Innovators” workshop marks a significant step forward in Karnataka’s vision to cultivate a knowledge-led innovation economy, ensuring that academic discoveries translate into impactful, real-world solutions.
technology
Vedanta Aluminium Secures Patent for Breakthrough Graphite Recovery Technology on National Technology Day 2025
In a landmark achievement announced on National Technology Day 2025, Vedanta Aluminium, India’s largest aluminium producer, revealed that it has been granted a patent for a pioneering technology that enables the recovery of graphite with over 99% purity from aluminium production waste. This breakthrough positions the company—and the country—at the forefront of sustainable manufacturing and critical mineral independence.
Turning Waste into Strategic Wealth
Reflecting this year’s theme, ‘YANTRA – Yugantar for Advancing New Technology, Research & Acceleration’, Vedanta’s patented innovation transforms industrial waste into a high-value resource, exemplifying the ethos of circular economy and deep-tech advancement.
The technology recovers battery-grade graphite from two hazardous waste streams in aluminium production—Spent Pot Lining (SPL) and Shot Blast Dust. These materials, previously considered non-recoverable and environmentally challenging, are now being repurposed into a strategic asset critical for India’s clean energy future.
A Critical Boost for India’s Mineral Security
The graphite recovered through this technology exhibits exceptional electrical conductivity and robust structural properties, making it ideally suited for use in lithium-ion batteries. Its atomic structure supports efficient lithiation and de-lithiation cycles, which are essential for energy storage systems in electric vehicles, renewable energy integration, and consumer electronics.
The new technology has the potential to significantly reduce this dependency. As one of the top three graphite importers in the Asia-Pacific region—alongside South Korea and Japan—India now has an opportunity to become self-reliant in this critical mineral segment.
Driving Sustainable Innovation
The achievement is emblematic of a larger shift in Indian industry toward innovation-led sustainability. By unlocking new value from what was once waste, Vedanta Aluminium is setting a precedent for responsible industrial practices that support both economic growth and environmental stewardship.
The company’s graphite recovery initiative also contributes to global climate goals by enabling cleaner energy technologies while reducing the environmental burden of industrial waste. It represents a scalable, replicable model for circular economy integration in heavy industry.
Looking Ahead
As India accelerates its transition to a green and self-reliant economy, innovations like Vedanta’s graphite recovery technology will play a critical role in bridging the gap between sustainability and industrial competitiveness. The patent marks not just a technological breakthrough, but a strategic leap toward a cleaner, more resilient future for India.
FEG Global Secures Patent for Innovative Emissions Scrubber, Eyes UK and European Expansion
An innovative engineering firm specializing in industrial equipment for the food manufacturing sector is set to expand its footprint across the UK and Europe after receiving full patent approval for its breakthrough emissions control product.
FEG Global, headquartered in Washington, UK, has developed the LGC Scrubber, a patented system designed to revolutionize odour and oil mist management in food production facilities. The technology is aimed at companies involved in high-temperature frying, cooking, coating, or seasoning—common in seafood, meat, poultry, ready meals, and snack food manufacturing.
The LGC Scrubber features a dual-function system that combines a particulate wet scrubber and a gas scrubber. This allows it to effectively capture and eliminate both oil mist and volatile odour compounds from industrial food processing operations. Its modular design makes it adaptable for integration into existing factory layouts, providing a practical and scalable solution for food manufacturers.
One of the standout benefits of the LGC Scrubber is its potential contribution to the circular economy. The system allows for the collection and possible repurposing of waste emissions—such as oil particles—as biofuel, opening up additional revenue streams for users.
Following the patent approval, FEG Global plans to ramp up sales and installations of the LGC Scrubber across European markets. The company already operates regional offices in the Midlands, Glasgow, and Belgium, positioning it strategically for cross-border growth.
Chris Williams, Managing Director of FEG Global, emphasized the broader impact of the innovation:
The LGC Scrubber is not just a technical achievement; it’s a practical, market-ready solution that addresses critical environmental and operational challenges for food manufacturers. As housing developments increasingly encroach on industrial zones, managing odours and emissions isn’t just good practice—it’s essential for regulatory compliance and community relations.”
The system has already been successfully implemented by Whitby Seafoods, one of the UK’s largest seafood processors known for its iconic Whitby Scampi. The company, which processes over 3,000 tonnes of scampi annually, required a reliable system to manage odours in its high-temperature production environment.
Chris Dickinson, Head of Engineering at Whitby Seafoods, praised the partnership:
“We needed a solution that met our environmental standards while integrating seamlessly into our operational setup. FEG Global delivered exactly that. The LGC Scrubber installation has allowed us to maintain high production volumes while ensuring we continue to meet our environmental responsibilities as a local employer and good neighbour.”
As regulatory pressures mount and community awareness grows around industrial emissions, FEG Global’s LGC Scrubber is poised to become a critical solution for food manufacturers seeking to future-proof their operations while maintaining environmental stewardship.
“Judge Signals Sanctions Against Patent Attorney for Sharing Netflix’s Confidential Data with Litigation Funder”
A federal judge in Oakland has signaled his intent to impose sanctions on patent attorney Bill Ramey and his firm, Ramey LLP, for violating a protective order by sharing Netflix Inc.’s confidential information with a litigation funder. The case stems from a patent infringement lawsuit filed by Finnish inventor Lauri Valjakka against Netflix, in which Ramey represented Valjakka.
During a hearing the U.S. District Court indicated that attorneys’ fees would be an appropriate sanction, noting that they would likely be substantial. The dispute centers on Ramey’s disclosure of Netflix’s source code and financial information to AiPi LLC, a litigation funding company, without proper authorization. Netflix contends that these materials, described as the “crown jewels of its business,” were shared in violation of the court’s protective order, which restricts access to sensitive information to authorized individuals only.
At the hearing, Netflix’s attorney, Sarah Piepmeier of Perkins Coie, argued that AiPi had access to the confidential information before Netflix was aware of the funding arrangement. She expressed concern that AiPi’s possession of Netflix’s proprietary data could influence its decisions in future litigation or inspire new lawsuits. Ramey defended his actions, asserting that the protective order allowed him to share the information with “affiliates,” a category he believed included AiPi’s attorneys. He further claimed that no harm had occurred because AiPi’s lawyers assured him they hadn’t used the materials inappropriately.
Judge Tigar expressed skepticism about Ramey’s defense, stating that having individuals affiliated with a litigation funder review Netflix’s source code constituted a situation of harm. He also indicated that he would consider referring Ramey to the California State Bar or another disciplinary body for further review.
This development adds to a series of legal challenges faced by Ramey and his firm. Earlier this year, Judge Tigar denied Ramey’s application for pro hac vice admission in a separate case, CyboEnergy Inc. v. Netflix Inc., ruling that Ramey had been practicing law in California without a state bar license. Additionally, Ramey has faced scrutiny over his firm’s handling of multiple patent cases in California without proper licensure, leading to questions about his compliance with state ethical standards .
The case, Valjakka v. Netflix Inc., continues to unfold, with potential implications for the intersection of patent law, litigation funding, and the protection of confidential business information.
During a hearing the U.S. District Court indicated that attorneys’ fees would be an appropriate sanction, noting that they would likely be substantial. The dispute centers on Ramey’s disclosure of Netflix’s source code and financial information to AiPi LLC, a litigation funding company, without proper authorization. Netflix contends that these materials, described as the “crown jewels of its business,” were shared in violation of the court’s protective order, which restricts access to sensitive information to authorized individuals only.
At the hearing, Netflix’s attorney, Sarah Piepmeier of Perkins Coie, argued that AiPi had access to the confidential information before Netflix was aware of the funding arrangement. She expressed concern that AiPi’s possession of Netflix’s proprietary data could influence its decisions in future litigation or inspire new lawsuits. Ramey defended his actions, asserting that the protective order allowed him to share the information with “affiliates,” a category he believed included AiPi’s attorneys. He further claimed that no harm had occurred because AiPi’s lawyers assured him they hadn’t used the materials inappropriately.
Judge Tigar expressed skepticism about Ramey’s defense, stating that having individuals affiliated with a litigation funder review Netflix’s source code constituted a situation of harm. He also indicated that he would consider referring Ramey to the California State Bar or another disciplinary body for further review.
This development adds to a series of legal challenges faced by Ramey and his firm. Earlier this year, Judge Tigar denied Ramey’s application for pro hac vice admission in a separate case, CyboEnergy Inc. v. Netflix Inc., ruling that Ramey had been practicing law in California without a state bar license. Additionally, Ramey has faced scrutiny over his firm’s handling of multiple patent cases in California without proper licensure, leading to questions about his compliance with state ethical standards .
The case, Valjakka v. Netflix Inc., continues to unfold, with potential implications for the intersection of patent law, litigation funding, and the protection of confidential business information.
Apple Patent Hints at Future Mac Devices with Gesture Control and Interactive Projection Surfaces
Apple Inc. has been granted a new patent that reveals ambitious plans to revolutionize how users interact with its computing devices. The patent outlines technology that could transform future MacBooks, iMacs, Magic Mouse, and Magic Keyboards by embedding a range of advanced sensors and projection systems. These innovations aim to enable gesture-based control, enhanced spatial awareness, and interactive visual displays projected onto nearby surfaces.
A New Era of Gesture-Driven Input
At the core of the patent is the integration of gesture recognition capabilities that go beyond current trackpads and touch input. According to the document, the proposed system will utilize a combination of position sensors, light sources, and image sensors to determine the precise location and motion of a device such as a mouse or keyboard. These sensors would not only track device movement on a surface but also interpret hand and finger gestures made in the air near the device.
Apple envisions using technologies such as visible and infrared cameras, capacitive sensors, ultrasonic modules, and accelerometers to recognize and interpret three-dimensional gestures. This would allow users to perform tasks by simply moving their hands above or beside the device, offering a touchless control experience. Such an approach could be particularly useful for accessibility, creative applications, or sterile environments where physical contact should be minimized.
Turning Surfaces into Smart Interfaces
One of the most striking features detailed in the patent is the use of miniature projectors embedded within devices like the MacBook or Magic Mouse. These projectors would be capable of casting virtual elements—such as labeled keys, buttons, or other UI elements—onto nearby surfaces. The projected images could then be interacted with through gestures or taps, effectively expanding the device’s interface beyond its physical form.
This concept has the potential to transform an ordinary desk into an extended digital workspace. For instance, a user could have projected function keys beside their MacBook that respond to finger taps or swipes, creating a dynamic, context-sensitive input surface.
Intelligent Feedback and Enhanced Input Detection
Apple’s design also includes the use of haptic feedback components that respond to user gestures. When a user interacts with the projected interface or moves their fingers along sensor-equipped sidewalls, haptic actuators could provide tactile responses to simulate button presses or surface texture changes.
In addition, embedded accelerometers may detect subtle vibrations transmitted through surfaces when users tap or move their fingers. This data could further refine gesture recognition, enabling high-precision input even on non-traditional interaction planes.
Implications for Future Apple Devices
The patent suggests that this technology could be applied across various Apple products, with particular emphasis on peripherals like the Magic Mouse and Keyboard, as well as the MacBook and iMac lines. By transforming passive input devices into intelligent, gesture-aware, and surface-interactive tools, Apple is laying the groundwork for a new user experience paradigm.
While the company has not officially announced any product using this technology, the patent signals Apple’s continued exploration of spatial computing and immersive interfaces. If implemented, this system could mark a significant step toward seamless, intuitive control across both 2D and 3D input environments.
Looking Ahead
This patent complements Apple’s broader efforts in augmented reality, wearable tech, and spatial computing—an area gaining traction with devices like Vision Pro. As Apple moves to unify its ecosystem with richer, more natural user interactions, the concepts in this patent may soon move from paper to product.
Disclaimer: While patents offer a glimpse into future product directions, not all patented technologies make it into commercial products. However, Apple’s consistent investment in gesture-based and sensor-driven innovations makes this development one to watch.
Unilin Technologies Secures European Patent for Groundbreaking Osiris Wood Recycling Technology
Unilin Technologies, the intellectual property division of Unilin, has been awarded European patent EP 4114629 for its pioneering Osiris recycling technology. This patent marks a significant milestone in the company’s mission to foster circular practices in the wood industry and reflects Unilin’s ongoing investment in sustainable innovation.
The patented Osiris system represents the first industrial-scale technology capable of recycling fiberboards—a long-standing challenge in the wood-based panel industry. Historically, the composite structure of fiberboards, which combines wood fibers with adhesives and resins, made them difficult to disassemble and therefore unfit for effective recycling. As a result, these boards typically ended up in landfills or were incinerated, contributing to environmental degradation.
With Osiris, Unilin has developed a scalable and practical solution to this issue. The technology enables the efficient separation of wood fibers from waste fiberboards, which can then be reintegrated with virgin wood to manufacture new fiberboards. This process not only reduces waste but also conserves natural resources by decreasing reliance on fresh wood material.
The Osiris technology is exclusively offered for licensing by Unilin Technologies in partnership with Dieffenbacher, a leading provider of wood-based panel production systems.
“We are proud to receive this patent, which underscores the innovation behind Osiris and the impact it can have on the sustainability of the fiberboard industry,” said a spokesperson from Unilin Technologies. “Our goal is to create real-world solutions that allow manufacturers to reduce their environmental footprint while maintaining high production standards.”
The granting of this European patent further strengthens Unilin’s intellectual property portfolio and opens the door for wider adoption of circular technologies across the board manufacturing sector. With global attention increasingly focused on sustainable production methods, Osiris offers a viable path forward for companies seeking to align with environmental targets without compromising efficiency or quality.
The patented Osiris system represents the first industrial-scale technology capable of recycling fiberboards—a long-standing challenge in the wood-based panel industry. Historically, the composite structure of fiberboards, which combines wood fibers with adhesives and resins, made them difficult to disassemble and therefore unfit for effective recycling. As a result, these boards typically ended up in landfills or were incinerated, contributing to environmental degradation.
With Osiris, Unilin has developed a scalable and practical solution to this issue. The technology enables the efficient separation of wood fibers from waste fiberboards, which can then be reintegrated with virgin wood to manufacture new fiberboards. This process not only reduces waste but also conserves natural resources by decreasing reliance on fresh wood material.
The Osiris technology is exclusively offered for licensing by Unilin Technologies in partnership with Dieffenbacher, a leading provider of wood-based panel production systems.
“We are proud to receive this patent, which underscores the innovation behind Osiris and the impact it can have on the sustainability of the fiberboard industry,” said a spokesperson from Unilin Technologies. “Our goal is to create real-world solutions that allow manufacturers to reduce their environmental footprint while maintaining high production standards.”
The granting of this European patent further strengthens Unilin’s intellectual property portfolio and opens the door for wider adoption of circular technologies across the board manufacturing sector. With global attention increasingly focused on sustainable production methods, Osiris offers a viable path forward for companies seeking to align with environmental targets without compromising efficiency or quality.
Navigating the Genomics Revolution: The Evolving Role of Intellectual Property Protection
More than two decades after the landmark announcement of the Human Genome Project’s completion in 2003, the field of genomics is undergoing a profound transformation. What began as a focus on decoding linear DNA sequences has expanded into a multidisciplinary understanding of the genome’s structural and functional complexity. This includes insights into protein folding, post-translational modifications like glycosylation, and the critical functions of non-coding DNA segments once dismissed as “junk,” such as introns.
In healthcare, personalized medicine, pharmacogenomics, and CRISPR-Cas9 gene editing are transitioning from research to real-world application. Genomic research is also driving the development of disease-resistant crops in agriculture and, in the biotech industry, is converging with artificial intelligence (AI) to accelerate innovations like next-generation sequencing and data interpretation.
This rapid evolution brings renewed focus on how intellectual property (IP) laws can safeguard innovation while keeping pace with scientific complexity. A strategic approach to IP is essential to protect genomics-related breakthroughs across multiple domains.
Patents: The Traditional Tool — and Its Limitations
Utility patents remain a cornerstone of IP strategy in genomics. In the competitive life sciences market, such exclusivity can determine commercial viability. However, the scope of what is patentable, especially in the U.S., is becoming increasingly restrictive.
Key genomic discoveries — like isolated human genes — when naturally occurring, are not patentable under U.S. law. Similarly, diagnostic methods that link biomarkers with disease states often fall outside the scope of patent-eligible subject matter. AI-driven components, such as algorithms used to interpret genomic data, also face hurdles, as abstract ideas and software in isolation typically don’t qualify for patent protection.
Disclosure Challenges in Patent Law
Patents require inventors to fully disclose their invention. This becomes problematic when critical elements of an innovation — like proprietary algorithms or data models — aren’t patentable but are vital to the invention’s function. In such cases, companies may be reluctant to disclose sensitive information that could be exploited by competitors, forcing them to weigh the benefits of limited patent protection against the risk of exposing valuable trade secrets.
Trade Secrets: A Flexible but Fragile Option
When patenting isn’t viable or would reveal too much, trade secrets offer an alternative. This form of protection doesn’t require disclosure and isn’t limited by subject matter rules or duration, as long as the information remains confidential. Genomics-based innovations — such as algorithm development, data modeling, and experimental optimization — are well-suited to trade secret strategies.
However, trade secrets are vulnerable. A single leak — from an employee, partner, or regulatory disclosure — can irreversibly compromise protection. Therefore, robust internal controls, clear access policies, and legal safeguards are essential to maintain secrecy.
Copyright: Protecting the Expression of Genomic Insights
While traditionally associated with creative works, copyright law has found new relevance in the digital era. It now extends to software, source code, and potentially, some aspects of genomics-related data and algorithms. Unlike patents, copyright protects the expression of an idea, not the idea itself — which means competitors can replicate the core concept using different language or methods, provided they don’t copy the exact expression.
For genomics, copyright might apply to algorithmic code, databases, or visualization tools used in analyzing genetic data. However, it is a limited tool that works best in conjunction with other forms of IP protection.
Toward an Integrated IP Strategy for Genomics
As genomics continues to push scientific boundaries, no single form of IP protection is sufficient. A multi-layered approach is often required — combining patents for core inventions, trade secrets for proprietary methods or data, and copyright for software or data presentation.
Careful coordination is essential. Over-disclosure in a patent could undermine trade secret protection, while an overly secretive approach might prevent the grant of a meaningful patent. Developing a clear, strategic IP roadmap that aligns with scientific goals and commercial interests is critical for ensuring innovations are protected without sacrificing competitive advantage.
In healthcare, personalized medicine, pharmacogenomics, and CRISPR-Cas9 gene editing are transitioning from research to real-world application. Genomic research is also driving the development of disease-resistant crops in agriculture and, in the biotech industry, is converging with artificial intelligence (AI) to accelerate innovations like next-generation sequencing and data interpretation.
This rapid evolution brings renewed focus on how intellectual property (IP) laws can safeguard innovation while keeping pace with scientific complexity. A strategic approach to IP is essential to protect genomics-related breakthroughs across multiple domains.
Patents: The Traditional Tool — and Its Limitations
Utility patents remain a cornerstone of IP strategy in genomics. In the competitive life sciences market, such exclusivity can determine commercial viability. However, the scope of what is patentable, especially in the U.S., is becoming increasingly restrictive.
Key genomic discoveries — like isolated human genes — when naturally occurring, are not patentable under U.S. law. Similarly, diagnostic methods that link biomarkers with disease states often fall outside the scope of patent-eligible subject matter. AI-driven components, such as algorithms used to interpret genomic data, also face hurdles, as abstract ideas and software in isolation typically don’t qualify for patent protection.
Disclosure Challenges in Patent Law
Patents require inventors to fully disclose their invention. This becomes problematic when critical elements of an innovation — like proprietary algorithms or data models — aren’t patentable but are vital to the invention’s function. In such cases, companies may be reluctant to disclose sensitive information that could be exploited by competitors, forcing them to weigh the benefits of limited patent protection against the risk of exposing valuable trade secrets.
Trade Secrets: A Flexible but Fragile Option
When patenting isn’t viable or would reveal too much, trade secrets offer an alternative. This form of protection doesn’t require disclosure and isn’t limited by subject matter rules or duration, as long as the information remains confidential. Genomics-based innovations — such as algorithm development, data modeling, and experimental optimization — are well-suited to trade secret strategies.
However, trade secrets are vulnerable. A single leak — from an employee, partner, or regulatory disclosure — can irreversibly compromise protection. Therefore, robust internal controls, clear access policies, and legal safeguards are essential to maintain secrecy.
Copyright: Protecting the Expression of Genomic Insights
While traditionally associated with creative works, copyright law has found new relevance in the digital era. It now extends to software, source code, and potentially, some aspects of genomics-related data and algorithms. Unlike patents, copyright protects the expression of an idea, not the idea itself — which means competitors can replicate the core concept using different language or methods, provided they don’t copy the exact expression.
For genomics, copyright might apply to algorithmic code, databases, or visualization tools used in analyzing genetic data. However, it is a limited tool that works best in conjunction with other forms of IP protection.
Toward an Integrated IP Strategy for Genomics
As genomics continues to push scientific boundaries, no single form of IP protection is sufficient. A multi-layered approach is often required — combining patents for core inventions, trade secrets for proprietary methods or data, and copyright for software or data presentation.
Careful coordination is essential. Over-disclosure in a patent could undermine trade secret protection, while an overly secretive approach might prevent the grant of a meaningful patent. Developing a clear, strategic IP roadmap that aligns with scientific goals and commercial interests is critical for ensuring innovations are protected without sacrificing competitive advantage.
Conduit Pharmaceuticals Receives Additional Patent Approval for Lead Autoimmune Disease Asset
Conduit Pharmaceuticals Inc. (NASDAQ: CDT), a biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases, announced today that it has received further patent approval for its lead therapeutic asset targeting autoimmune conditions. The newly granted patent strengthens the company’s intellectual property portfolio and provides added protection for its innovative approach to treating autoimmune diseases such as sarcoidosis and lupus.
The patent, issued by the United States Patent and Trademark Office (USPTO), covers key methods of use and compositions relating to Conduit’s investigational drug, which is designed to modulate the immune response in patients with chronic autoimmune disorders. According to company officials, the approval not only broadens the existing patent family but also enhances the commercial potential of the lead compound as it advances through clinical development.
“This new patent grant is a major milestone for Conduit Pharmaceuticals, as it secures crucial proprietary rights over our lead autoimmune asset,” said Dr. David Tapolczay, Chief Executive Officer of Conduit Pharmaceuticals. “Our mission is to bring safe and effective treatments to patients suffering from complex autoimmune conditions, and this patent approval is a significant step forward in protecting the innovation that underpins our approach.”
The company’s lead asset, originally acquired from a major pharmaceutical partner, has demonstrated promising results in preclinical and early clinical studies. The drug works by selectively targeting pathways involved in the overactive immune response characteristic of autoimmune diseases, while minimizing systemic immunosuppression.
Conduit Pharmaceuticals has emphasized its strategy of revitalizing underutilized assets from larger pharmaceutical companies and accelerating them through late-stage development. The expanded patent protection ensures a longer runway for exclusivity, which could facilitate future licensing agreements or commercial partnerships.
Industry analysts view the patent approval as a positive development that enhances Conduit’s valuation and strengthens its position in the competitive autoimmune drug market, projected to surpass $150 billion globally by 2030.
The company plans to continue progressing its lead candidate through clinical trials, with additional updates expected later this year regarding regulatory filings and potential Phase 2 study initiations.
For more information, visit www.conduitpharma.com.
Agfa Loses Patent Dispute Against Gucci Over Leather Decoration Method
Printing technology company Agfa has filed a patent infringement lawsuit against luxury fashion house Gucci, alleging unauthorized use of its patented method for decorating natural leather. The legal battle centered on Agfa’s European patent EP 3 388 490, which covers a process for embellishing leather surfaces with decorative images—a technique the company considers vital to its future innovation strategy.
The dispute specifically involved Gucci’s Pikarar Collection, which Agfa claimed employed its patented method without authorization. However, the Local Division of the Unified Patent Court (UPC) in Hamburg dismissed both Agfa’s infringement claim and Gucci’s counterclaim for patent invalidation (Case ID: ACT_561734/2023).
Presiding Judge Sabine Klepsch and her panel deemed both the infringement action and the revocation counterclaim admissible, but ultimately ruled against both parties. The court’s decision was based on a detailed analysis of the patent language, drawing on precedent established in earlier UPC rulings, such as the NanoString vs. 10x Genomics case. The court concluded that the interpretation of certain terms in the patent should differ from their conventional meanings, resulting in a finding of no infringement on Gucci’s part.
This case marks the first time a luxury fashion brand has been involved in litigation before the newly established Unified Patent Court. The ruling offers some relief to the fashion industry, although Agfa still has the option to appeal.
Agfa was represented by a legal team jointly led by Daan de Lange of the Netherlands and Kai Rüting of Germany. The case also marked the first major matter handled by Vossius Brinkhof UPC Litigators, a new collaboration between Dutch and German law firms. Other members of the legal team included Stefan Fickert, Ananda Landwehr, Leonie Dissmann-Fuchs, Elard Schenck zu Schweinsberg, Isabelle Kleinveld, and Alexander de Leeuw. Hans Louis Strijckers managed the case internally for Agfa.
Although the decision did not go in Agfa’s favor, the company’s aggressive defense of its patent portfolio signals its strategic focus on emerging technologies in leather decoration.
The dispute specifically involved Gucci’s Pikarar Collection, which Agfa claimed employed its patented method without authorization. However, the Local Division of the Unified Patent Court (UPC) in Hamburg dismissed both Agfa’s infringement claim and Gucci’s counterclaim for patent invalidation (Case ID: ACT_561734/2023).
Presiding Judge Sabine Klepsch and her panel deemed both the infringement action and the revocation counterclaim admissible, but ultimately ruled against both parties. The court’s decision was based on a detailed analysis of the patent language, drawing on precedent established in earlier UPC rulings, such as the NanoString vs. 10x Genomics case. The court concluded that the interpretation of certain terms in the patent should differ from their conventional meanings, resulting in a finding of no infringement on Gucci’s part.
This case marks the first time a luxury fashion brand has been involved in litigation before the newly established Unified Patent Court. The ruling offers some relief to the fashion industry, although Agfa still has the option to appeal.
Agfa was represented by a legal team jointly led by Daan de Lange of the Netherlands and Kai Rüting of Germany. The case also marked the first major matter handled by Vossius Brinkhof UPC Litigators, a new collaboration between Dutch and German law firms. Other members of the legal team included Stefan Fickert, Ananda Landwehr, Leonie Dissmann-Fuchs, Elard Schenck zu Schweinsberg, Isabelle Kleinveld, and Alexander de Leeuw. Hans Louis Strijckers managed the case internally for Agfa.
Although the decision did not go in Agfa’s favor, the company’s aggressive defense of its patent portfolio signals its strategic focus on emerging technologies in leather decoration.
AI Tools Accelerate Insights in CAR T-Cell Therapy Research for Multiple Myeloma
A research team focused on advancing chimeric antigen receptor (CAR) T-cell therapies has harnessed artificial intelligence tools to streamline data analysis and extract key insights in the field. Their work was highlighted as part of the late-breaking research presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois.
The investigators explored the evolving landscape of CAR T-cell treatments for multiple myeloma (MM) by leveraging two AI-powered platforms: BiblioEngine, developed by 23Strands, and Cool.AF from Neural Hinge. These tools were used to mine publicly accessible clinical literature, with a focus on manufacturing methods, clinical trial structures, and therapeutic outcomes. The team also conducted a comprehensive review of related patent filings across jurisdictions including the United States, European Union, and India.
By utilizing AI-driven analytics, the researchers efficiently processed large volumes of data and identified emerging trends in how CAR T-cell therapies are developed and applied in real-world clinical settings. The tools enabled detailed comparisons between datasets, shedding light on factors influencing successful patent applications and highlighting the structure of collaborative networks among researchers in the field.
The analysis not only revealed current gaps in MM treatment strategies but also pointed to opportunities for future innovation and patent development. These findings are expected to guide more strategic clinical trial design and support intellectual property planning that avoids overlap with existing patents.
Moreover, the team’s work identified opportunities to foster new research partnerships by mapping the relationships among authors in the field, potentially expanding the collaborative network and accelerating progress in CAR T-cell therapy innovation.
The investigators explored the evolving landscape of CAR T-cell treatments for multiple myeloma (MM) by leveraging two AI-powered platforms: BiblioEngine, developed by 23Strands, and Cool.AF from Neural Hinge. These tools were used to mine publicly accessible clinical literature, with a focus on manufacturing methods, clinical trial structures, and therapeutic outcomes. The team also conducted a comprehensive review of related patent filings across jurisdictions including the United States, European Union, and India.
By utilizing AI-driven analytics, the researchers efficiently processed large volumes of data and identified emerging trends in how CAR T-cell therapies are developed and applied in real-world clinical settings. The tools enabled detailed comparisons between datasets, shedding light on factors influencing successful patent applications and highlighting the structure of collaborative networks among researchers in the field.
The analysis not only revealed current gaps in MM treatment strategies but also pointed to opportunities for future innovation and patent development. These findings are expected to guide more strategic clinical trial design and support intellectual property planning that avoids overlap with existing patents.
Moreover, the team’s work identified opportunities to foster new research partnerships by mapping the relationships among authors in the field, potentially expanding the collaborative network and accelerating progress in CAR T-cell therapy innovation.